source · text/markdown
source_b51114f089d0489d
sha256 9b0d0232ae466ee31a2193fd858695d7dd94bf1b1254af9adf7ab882f7c92e9d
by researka:v2 · 2026-07-03 17:39:41.057205+04:00
# Source literature boundary memo ## Research question Across retrieved source-level receipts for fisetin, which endpoints show directionally favorable versus null/non-convergent signals, and what matched PICO remains untested? ## Selection criteria The source-literature selector kept fisetin because the candidate bundle met the public source rule: 5 citable papers, 5 distinct fact-backed source identities, topic-overlapping source facts, and enough shared scope to compare metric/context disagreement. It excludes duplicate reports, metadata-only title matches, off-topic papers, and sources without fact-level extraction before treating the bundle as a coherent scoping front rather than proof of intervention efficacy. ## Plain-language synthesis Bounded signal: fisetin is only a source-level context map; the selected receipts do not establish one pooled effect. ## Boundary map - Intermittent supplementation with fisetin improves arterial function in old mice by decreasing cellular senescence [primary; 2023] doi:10.1111/acel.14060 - Finding: IC50 of fisetin 3.4 ± 0.3 μM on senescent cells versus 7.0 ± 0.4 μM on control cells - Population: senescent human umbilical vein endothelial cells (HUVECs) - Intervention/exposure: fisetin - Comparator: nonsenescent control HUVECs (IC50 7.0 ± 0.4 μM) - <p>Antiviral and immunomodulatory effects of polyphenols on macrophages infected with dengue virus serotypes 2 and 3 enhanced or not with antibodies</p> [primary; 2019] doi:10.2147/idr.s210890 - Finding: Only quercetin and fisetin inhibited DENV-2 and DENV-3 infection in the absence or presence of enhancing antibody (>90%, p<0.001); - Population: Human U937-DC-SIGN macrophages infected with dengue virus serotypes 2 or 3 - Intervention/exposure: quercetin and fisetin - Comparator: infection without polyphenols - Dual targeting of mTOR/IL-17A and autophagy by fisetin alleviates psoriasis-like skin inflammation [primary; 2023] doi:10.3389/fimmu.2022.1075804 - Finding: 12,713 differentially expressed genes (DEGs) in the fisetin-treated group compared to 7,374 DEGs in the rapamycin-treated group - Population: HEKa cells (adult human epidermal keratinocytes) - Intervention/exposure: fisetin treatment - Comparator: rapamycin treatment - Fisetin, a 3,7,3′,4′-Tetrahydroxyflavone Inhibits the PI3K/Akt/mTOR and MAPK Pathways and Ameliorates Psoriasis Pathology in 2D and 3D Organotypic Human Inflammatory Skin Models [primary; 2019] doi:10.3390/cells8091089 - Finding: Fisetin treatment significantly inhibited the activation of p38 and JNK, but had enhanced effect on ERK1/2. - Population: TNF-α stimulated NHEKs - Intervention/exposure: fisetin - Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics [primary; 2023] doi:10.3390/ph16020196 - Finding: The daily uptake of fisetin was calculated to be an average of 0.4 milligrams. - Population: general human intake - Intervention/exposure: fisetin ## Source synthesis Bounded signal: fisetin is only a source-level context map; the selected receipts do not establish one pooled effect. ## Evidence matrix ### Effect-bearing comparison | Outcome family | Receipt | Evidence role | Population/setting | Metric | Extracted finding | |---|---|---|---|---|---| | outcome-specific | <p>Antiviral and immunomodulatory effects of polyphenols on... | directionally favorable | Human U937-DC-SIGN macrophages infected with... | - | Only quercetin and fisetin inhibited DENV-2 and DENV-3 infection in the absence or presence of enhancing... | | outcome-specific | Fisetin, a 3,7,3′,4′-Tetrahydroxyflavone Inhibits the PI3K/Akt/mTOR and... | directionally favorable | TNF-α stimulated NHEKs | - | Fisetin treatment significantly inhibited the activation of p38 and JNK, but had enhanced effect on ERK1/2 | ### Context-only receipts | Outcome family | Receipt | Evidence role | Population/setting | Metric | Extracted finding | |---|---|---|---|---|---| | outcome-specific | Intermittent supplementation with fisetin improves arterial function in... | other/mixed | senescent human umbilical vein endothelial... | - | IC50 of fisetin 3.4 ± 0.3 μM on senescent cells versus 7.0 ± 0.4 μM on control cells | | outcome-specific | Dual targeting of mTOR/IL-17A and autophagy by fisetin alleviates... | other/mixed | HEKa cells (adult human epidermal keratinocytes) | - | 12,713 differentially expressed genes (DEGs) in the fisetin-treated group compared to 7,374 DEGs in the... | | outcome-specific | Fisetin in Cancer: Attributes, Developmental Aspects, and... | other/mixed | general human intake | - | The daily uptake of fisetin was calculated to be an average of 0.4 milligrams | This receipt-backed scoping note has one bounded signal: fisetin shows endpoint-specific favorable signals with context limits across this 5-source primary bundle (2019-2023). Evidence role grouping: direction-bearing receipts: 2; null/mixed metric-scope caveat receipts: 0; context/antecedent/model receipts: 3 excluded from effect support. The source facts cover 5 population/setting context(s) and 3 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. The listed effect sizes remain source-specific across endpoints and populations; they are not pooled or averaged. This is a heterogeneous indication/context map, not a unified disease-specific or endpoint-family claim. Concrete contrast: other/mixed: Intermittent supplementation with fisetin improves arterial function in old mice by decreasing cellular senescence: IC50 of fisetin 3.4 ± 0.3 μM on senescent cells versus 7.0 ± 0.4 μM on control cells; directionally favorable: <p>Antiviral and immunomodulatory effects of polyphenols on macrophages infected with dengue virus serotypes 2 and 3 enhanced or not with antibodies</p>: Only quercetin and fisetin inhibited DENV-2 and DENV-3 infection in the absence or presence of enhancing.... ## Directional grouping - directionally favorable: fisetin is the intervention/exposure and the reported clinical endpoint favors that arm. - comparator/not favorable: fisetin is the comparator arm; the label is limited to that head-to-head endpoint. - economic/context only: the receipt reports cost, QALY, or economic context rather than a clinical efficacy endpoint. - non-clinical/predictive: the receipt reports descriptive modelling, prediction, or age-clock performance rather than an intervention endpoint. - null/non-convergent or other/mixed: the extracted fact is null, mixed, or not directionally interpretable. - other/mixed: Intermittent supplementation with fisetin improves arterial function in old mice by decreasing cellular senescence — IC50 of fisetin 3.4 ± 0.3 μM on senescent cells versus 7.0 ± 0.4 μM on control cells - directionally favorable: <p>Antiviral and immunomodulatory effects of polyphenols on macrophages infected with dengue virus serotypes 2 and 3 enhanced or not with antibodies</p> — Only quercetin and fisetin inhibited DENV-2 and DENV-3 infection in the absence or presence of enhancing antibody (>90%, p<0.001); ( mechanistic ablation supports the topic effect; not a comparator outcome) - other/mixed: Dual targeting of mTOR/IL-17A and autophagy by fisetin alleviates psoriasis-like skin inflammation — 12,713 differentially expressed genes (DEGs) in the fisetin-treated group compared to 7,374 DEGs in the rapamycin-treated group - directionally favorable: Fisetin, a 3,7,3′,4′-Tetrahydroxyflavone Inhibits the PI3K/Akt/mTOR and MAPK Pathways and Ameliorates Psoriasis Pathology in 2D and 3D Organotypic Human Inflammatory Skin Models — Fisetin treatment significantly inhibited the activation of p38 and JNK, but had enhanced effect on ERK1/2. ( mechanistic ablation supports the topic effect; not a comparator outcome) - other/mixed: Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics — The daily uptake of fisetin was calculated to be an average of 0.4 milligrams. Evidence role summary: direction-bearing receipts: 2; null/mixed metric-scope caveat receipts: 0; context/antecedent/model receipts: 3 excluded from effect support. Direction labels for audit: directionally favorable: 2 receipt(s) | other/mixed: 3 receipt(s). Specific moderators in this bundle are population/indication (HEKa cells (adult human epidermal keratinocytes); Human U937-DC-SIGN macrophages infected with dengue virus serotypes 2 or 3; TNF-α stimulated NHEKs; general human intake; senescent human umbilical vein endothelial cells (HUVECs)), study design/evidence type (primary). ## Context separation Population/settings are separated as receipt context: HEKa cells (adult human epidermal keratinocytes), Human U937-DC-SIGN macrophages infected with dengue virus serotypes 2 or 3, TNF-α stimulated NHEKs, general human intake, and senescent human umbilical vein endothelial cells (HUVECs). The selected receipts group because each carries a fact-level extraction for fisetin; they separate by context (human clinical/observational and other source context) and endpoint, so they are not interchangeable evidence for one pooled claim. ## Boundary limits Source-literature boundary for fisetin: the listed sources define one bounded, context-dependent signal across separate source contexts. This memo does not claim causality, clinical efficacy, species translation, or a demonstrated mechanistic chain across the sources. Material limitations: small 5-source bundle; no pooled estimate is possible; method/model receipts without direct effect estimates are context only; endpoints are not harmonized across studies. The signal is purely descriptive of source-level direction and scope; it cannot support even a weak causal or comparative-efficacy inference, and pooling across these PICOs would be inappropriate. Routing domain `longevity_research` is publication-lane metadata only; the source scope here is defined by the selected fisetin receipts. ## What would weaken this - This scoping signal would weaken if a matched rerun finds five citable, fact-backed receipts in one population, intervention, and endpoint frame that remove the reported boundary, if the direction-bearing rows fail to reproduce within their named endpoint family, or if the context-only rows are the only topic-overlapping receipts. ## Next gaps A stronger memo needs one matched PICO: one population, one intervention/exposure, one comparator, and one named outcome. If fisetin is promoted beyond a scoping note, the next run should select sources sharing one context family rather than spanning human clinical/observational and other source context.
metadata
{
"article_type": "alpha_memo",
"domain_slug": "longevity_research",
"researka_object_type": "submission",
"researka_submission_id": "dea7b0b8-af18-4449-ab93-a3b9ed0b8a04",
"title": "fisetin: one bounded, context-dependent signal across receipts"
}